Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
Conclusions: In conclusion, we demonstrated in pre-specified analyses that fenofibrate reduces albuminuria progression and may reduce loss of renal function. This appears to be independent of, and therefore additive to renin–angiotensin system blockade and glycaemic control. We found no evidence that the initial plasma creatinine rise represented true renal injury, a finding that has important implications for clinical care. The size and consistency of the estimated GFR and albuminuria benefits support use of fenofibrate in type 2 diabetes to reduce renal morbidity, especially in patients with dyslipidaemia.
Diabetologia
DOI 10.1007/s00125-010-1951-1
ldl-p (11)
